Pharmafile Logo

PHARMA POST COVID-19: REVOLUTION OR EVOLUTION?

- PMLiVE

Post-COVID-19 thinking: outputs from a thought leader forum

On 14 May 2020, a group of industry experts across pharma and biotech Zoomed together to share reflections on the impact of COVID-19 so far and the implications for how we should evolve in the coming months and years:
Download full article here

EXECUTIVE SUMMARY

Biggest impact of COVID-19

  • COVID-19 has had a significant impact on how the industry works; maintaining individuals’ well-being and finding the best ways to integrate digital has challenged many companies
  • Clinical trials have been affected, in particular, recruitment and progress. It was also noted that certain metrics and data collection are likely to be affected and may have an impact on future regulatory submissions
  • Our forum concluded that in general we expect sales of established medicines to be above expectations, with newer therapies likely to be behind budget, due mainly to patients not attending clinic and a reduced new/switched/repeat dynamic

Biggest concerns

  • We highlighted concern that future pricing may be affected. Government debt has been affected by COVID-19 and this may impact future pricing negotiations and also see a quicker transition to outcomes-based pricing
  • Our recommendation is that the industry needs to continue to build trust. Vaccine and COVID-19 treatment costs will be high-profile negotiations and may affect reputation or profits.
  • There is an opportunity for the industry to transition its reputation from medicines developers to healthcare providers
  • The industry needs to evolve how it works digitally, but we don’t expect a revolution, rather a gradual upskilling of organisations and of its people to enable more effective working. How this is done, however, is still uncertain, and is an opportunity for better collaboration

Biggest opportunities

  • We concluded that re-shaping how the field force evolve and work is a huge opportunity for the industry to add more value to society. How to add value through a truly multi-channel approach is an exciting opportunity for our industry, and a key opportunity for future discussion
  • The industry has spent millions on congress attendance for so many years. How the industry has recently operated offers an opportunity to re-think how to engage with congresses, but more importantly how to engage with healthcare professionals throughout the year. We don’t see a time when congresses are not important, but whether medical communications are anchored to congresses in the future is an opportunity to explore
  • It’s difficult to predict the new normal, but we know digital and user experience will be critical to effective commercialisation. This provides an exciting opportunity for our industry to create compelling digital experiences for brand and organisations to communicate with their audiences
  • We expect increased pricing pressure in the future. The organisations that adapt best, by providing real-world evidence, outcomes-based evidence and pricing, and support service re-design, will lead the future industry

Download full article here

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

How I’m helping to #BreakTheBias: International Women’s Day

What do you think of when you imagine a scientist? Who do you see in a lab coat? Gender stereotypes and assumptions are rife and, as a child, the thought...

Extraordinary lives: advancing change in rare diseases

Rare Disease Day is all about raising awareness and generating change for the 300 million people worldwide living with a rare disease. On this day across the globe, the rare...

Extraordinary lives: advancing change in rare diseases

We are extending the conversation for Rare Disease Day by continuing to raise awareness and generate change for the 300 million people worldwide living with a rare disease, their families...

Placing people at Lucid’s heart: Paul Cutler, Lucid Group’s new Chief People Officer

We interviewed Paul Cutler, Lucid Group’s new Chief People Officer, to find out a bit more about what makes him tick, why he chose to join Lucid, and what his...

A Lucid Group social

The newly formed Lucid Social Committee is launching its first event for the year: Today, on Thursday 24 February Lucid will be hosting its inaugural board games night in both...

Lucid Group Welcomes a New Cohort of Graduates into its Futures Academy

We are excited to welcome this year’s cohort of graduates into our Lucid Futures Academy, which is now into its sixth year after being launched in Oct 2017.The Futures Academy...

We let your whole self shine

People are at the heart of who we are. Our aim is to transform the lives of those we touch without prejudice or discrimination. At Lucid, the magic we create...

Climbing my own Lucid Ladder

Transforming lives. That’s what Lucid is all about. I knew that even before I stepped through the fabled door of ‘Towers’ on a chilly January morning in 2019. It’s why...

A Lucid Thirsty Thursday D&I Special

Last week’s ‘Thirsty Thursday’ session was organised by the Lucid Group D&I Committee, whose goal is to foster a culture where diversity and inclusivity are embedded and practised within all...

Connecting capabilities in healthcare communications

The account management/medical writing paradigm was the cornerstone of medcomms for many years, but evolution in technology, storytelling and an increasingly sophisticated audience has changed this.Instead, today's environment requires an integrated,...